Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACE1702

            Therapeutic Area: Oncology Product Name: ACE1702

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 07, 2021

            Details:

            Data support ACE1702 as off-the-shelf natural killer (NK) cell therapy against HER2-expressing cancers. ACE1702 overcomes limitations of current cancer cell therapies by enhancing the innate ability of NK cells to target and destroy HER2-expressing tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DBPR115

            Therapeutic Area: Oncology Product Name: DBPR115

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2021

            Details:

            DBPR115 small molecule drug delivery system has a lower production cost and is less likely to cause adverse immune reactions.